VISCHER advises investors in the CHF 20 million ($21 million) Series D financing of Genkyotex, in Plan-Les-Ouates - Geneva, Genkyotex focuses on developing drugs that stop the production of damaging oxygen species in the body (NOX inhibitors). The financing was led by NeoMed Management, who along with co-leads VI Partners and BioMedInvest are new investors in the Company. Proceeds will be used to complete a Phase 2 trial of GKT137831 in diabetic nephropathy, advance a second drug into Phase 1 trials, and broaden the Company’s pipeline of NOX inhibitors. The VISCHER Team was led by Dr. Matthias Staehelin (Partner) with Marius Meier (Managing Associate) and Dania Salvisberg-Schneider (Associate), all Corporate.